Covered recipient · General Payments record
TIMOTHY ALAN RICHARDSON
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$65,226.86
101 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,278.00 | 30 |
| Consulting Fee | $13,208.50 | 7 |
| Food and Beverage | $1,688.92 | 58 |
| Travel and Lodging | $1,301.44 | 5 |
| Honoraria | $750.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $22,642.01 | 21 |
| Myovant Sciences Inc. | $10,005.66 | 7 |
| Janssen Biotech, Inc. | $9,750.89 | 16 |
| Dendreon Pharmaceuticals LLC | $7,045.26 | 6 |
| Astellas Pharma US Inc | $6,191.41 | 14 |
| Merck Sharp & Dohme Corporation | $5,080.94 | 5 |
| Exelixis Inc. | $1,980.00 | 1 |
| Blue Earth Diagnostics Limited | $1,113.26 | 4 |
| ACCORD HEALTHCARE, INC. | $762.65 | 2 |
| PFIZER INC. | $109.03 | 6 |
| Medtronic, Inc. | $79.44 | 1 |
| Clarus Therapeutics Inc. | $74.70 | 1 |
| Verity Pharmaceuticals Inc. | $71.19 | 1 |
| Innovation Technologies Inc | $49.02 | 1 |
| Siemens Medical Solutions USA, Inc. | $38.16 | 1 |
| Foundation Medicine, Inc. | $37.62 | 2 |
| Allergan, Inc. | $36.63 | 2 |
| Myriad Genetic Laboratories, Inc. | $31.00 | 2 |
| COLOPLAST CORP | $28.14 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $23.07 | 1 |
| AstraZeneca Pharmaceuticals LP | $21.03 | 1 |
| Amgen Inc. | $19.69 | 1 |
| UROGEN PHARMA, INC. | $12.87 | 1 |
| Olympus America Inc. | $11.60 | 1 |
| AbbVie Inc. | $11.59 | 1 |
Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIMOTHY ALAN RICHARDSON
NPI 1508985417 · CMS profile ID 633917
Allopathic & Osteopathic Physicians / Urology
WICHITA, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
101 matching records · $65,226.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 101.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $1,625.00 | 08/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513713 | CMS |
| Astellas Pharma US Inc | $14.38 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513707 | CMS |
| PFIZER INC. | $12.80 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832778117 | CMS |
| Myovant Sciences Inc. | $368.48 | 07/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984761 | CMS |
| Myovant Sciences Inc. | $5,525.00 | 07/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984767 | CMS |
| Astellas Pharma US Inc | $15.13 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513701 | CMS |
| Myovant Sciences Inc. | $119.62 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984757 | CMS |
| Dendreon Pharmaceuticals LLC | $18.89 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851431315 | CMS |
| Dendreon Pharmaceuticals LLC | $238.07 | 07/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851431317 | CMS |
| Dendreon Pharmaceuticals LLC | $5,400.00 | 07/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851431319 | CMS |
| Merck Sharp & Dohme Corporation | $24.68 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848375165 | CMS |
| Blue Earth Diagnostics Limited | $17.66 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 844625563 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 07/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984753 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 06/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333941 | CMS |
| Clarus Therapeutics Inc. | $74.70 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855012449 | CMS |
| PFIZER INC. | $12.89 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832627011 | CMS |
| Astellas Pharma US Inc | $14.75 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513695 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $705.00 | 06/04/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789096425 | CMS |
| Astellas Pharma US Inc | $11.84 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513689 | CMS |
| AbbVie Inc. | $11.59 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795827951 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $934.00 | 05/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789154637 | CMS |
| Janssen Biotech, Inc. | $14.49 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333963 | CMS |
| Astellas Pharma US Inc | $13.69 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513683 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,401.00 | 05/05/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789152969 | CMS |
| Dendreon Pharmaceuticals LLC | $19.50 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851431313 | CMS |
| Exelixis Inc. | $1,980.00 | 05/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838867261 | CMS |
| Amgen Inc. | $19.69 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825838261 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333943 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333945 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $934.00 | 04/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789190295 | CMS |
| Myovant Sciences Inc. | $92.56 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984751 | CMS |
| Myriad Genetic Laboratories, Inc. | $17.52 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834566943 | CMS |
| Astellas Pharma US Inc | $13.37 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513677 | CMS |
| PFIZER INC. | $29.76 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832566651 | CMS |
| Olympus America Inc. | $11.60 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 800267051 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $467.00 | 03/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789100973 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,512.00 | 03/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789191389 | CMS |
| Merck Sharp & Dohme Corporation | $23.64 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848503095 | CMS |
| UROGEN PHARMA, INC. | $12.87 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826678699 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $705.00 | 03/11/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789040703 | CMS |
| Janssen Biotech, Inc. | $15.39 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788333961 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 03/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834984746 | CMS |
| Allergan, Inc. | $12.60 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792920515 | CMS |
| Blue Earth Diagnostics Limited | $16.85 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 844625547 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3,960.00 | 02/25/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789061109 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $23.07 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851935179 | CMS |
| Astellas Pharma US Inc | $13.77 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513671 | CMS |
| Astellas Pharma US Inc | $1,410.00 | 02/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513665 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $934.00 | 02/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789150749 | CMS |
| Astellas Pharma US Inc | $1,410.00 | 01/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821513659 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,011,167.14 | 102 |
| PY2024 | Principal investigator | $1,135,170.18 | 154 |
| PY2023 | Principal investigator | $885,930.30 | 110 |
| PY2022 | Principal investigator | $756,095.87 | 23 |
| PY2021 | Principal investigator | $562,671.79 | 35 |
| PY2020 | Principal investigator | $254,093.18 | 91 |
| PY2019 | Principal investigator | $160,394.28 | 110 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
102 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,597.08 | 12/31/2025 | Non-covered Recipient Entity Wichita Urology Group | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232925203 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Wichita Urology Group | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $55,650.00 | 12/29/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175380437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,247.00 | 12/29/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175380675 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,027.00 | 12/22/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175380293 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,000.00 | 12/18/2025 | Non-covered Recipient Entity Urology Group Wichita | A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w | No dispute reported | 06/30/2026 | 1190305043 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,475.00 | 11/12/2025 | Non-covered Recipient Entity Wichita Urology Group PA | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,156.00 | 11/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175380164 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 11/05/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654641 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,505.00 | 11/05/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654690 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 11/05/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176655064 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,236.20 | 10/27/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP, PA | A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w | No dispute reported | 06/30/2026 | 1190303925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $382.00 | 10/13/2025 | Non-covered Recipient Entity XCANCER OMAHA LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175347013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $473.00 | 10/13/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175380650 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,415.10 | 10/05/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP, PA | TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combin | No dispute reported | 06/30/2026 | 1190303927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,222.00 | 10/03/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175380503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,602.00 | 10/02/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175380665 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,692.00 | 09/08/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,482.00 | 09/08/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 09/08/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380415 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $313.08 | 08/31/2025 | Non-covered Recipient Entity Wichita Urology Group | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $120.00 | 08/28/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $533.00 | 08/18/2025 | Non-covered Recipient Entity XCANCER OMAHA LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175346617 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,897.00 | 08/11/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 08/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 08/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380444 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30.00 | 08/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $706.00 | 08/04/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $706.00 | 08/04/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380523 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 08/01/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,548.00 | 07/28/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $791.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380539 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,702.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380592 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $791.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380632 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/18/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380728 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 07/09/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640261 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 07/09/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640326 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,505.00 | 07/09/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640403 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,542.00 | 07/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,552.00 | 07/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 07/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $225.00 | 07/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380761 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,275.00 | 06/30/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380330 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $676.50 | 06/12/2025 | Non-covered Recipient Entity Wichita Urology Group PA | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225402495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,904.00 | 06/06/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175380385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,957.00 | 06/02/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175380658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,464.00 | 05/19/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380376 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,000.00 | 05/19/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380625 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,048.00 | 05/12/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380472 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,487.50 | 05/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634265 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,937.50 | 05/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634274 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,527.00 | 04/28/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,412.00 | 04/25/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175380754 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 04/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 04/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $890.00 | 04/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380531 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 04/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380577 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,252.50 | 04/09/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632783 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $13,972.50 | 04/09/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP PA | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,639.00 | 04/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,501.00 | 04/07/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $382.00 | 03/31/2025 | Non-covered Recipient Entity GU RESEARCH NETWORK LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175346870 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,597.00 | 03/27/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380690 |
| Principal investigator 1 | Janssen Research & Development, LLC | $650.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380218 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,597.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,939.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $342.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380361 |
| Principal investigator 1 | Janssen Research & Development, LLC | $342.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,939.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/14/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380698 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,043.00 | 03/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,483.00 | 03/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175380707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,638.00 | 02/10/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380713 |
| Principal investigator 1 | Janssen Research & Development, LLC | $533.00 | 02/03/2025 | Non-covered Recipient Entity GU RESEARCH NETWORK LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175346974 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 01/30/2025 | Non-covered Recipient Entity Wichita Urology Group PA | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225405258 |
| Principal investigator 1 | Janssen Research & Development, LLC | $525.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380156 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380204 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380277 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380354 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380429 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380454 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/24/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380736 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,078.00 | 01/23/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380265 |
| Principal investigator 1 | Janssen Research & Development, LLC | $212.00 | 01/23/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,769.00 | 01/23/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380584 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $161,396.40 | 01/16/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP, PA | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185547907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $86,302.00 | 01/02/2025 | Non-covered Recipient Entity WICHITA UROLOGY GROUP | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175380513 |